Novo Nordisk’s ziltivekimab misses Phase 3 primary endpoint
Phase 3negativeziltivekimabNegative
AI Analysis
Summary
Novo Nordisk's ziltivekimab failed to meet its Phase 3 primary endpoint of reducing major adverse cardiovascular events, despite demonstrating the expected biological effect targeting IL-6 ligand.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Failed to reduce risk of major adverse cardiovascular events (MACE) in Phase 3 trial; produced expected biological effect but no MACE benefits
Importance:8/10
Sentiment:
-0.85
Phase 3 failurecardiovascularmonoclonal antibodyIL-6 pathway
Related Companies
Read the original article
Published by Drug Discovery & Development on August 12, 2026 4:21 PM